Smith and NephewSmith and Nephew released their results. Below is the acticoat mention.
Advanced Wound Management
The Advanced Wound Management division generated underlying sales growth of 6%, both inside and outside the US. This improvement in growth in the US reflects the reducing impact of the switch in enzyme debrider products. Sales growth, in the US, excluding enzyme debriders was 15%. Outside the US, healthcare reforms in Europe, particularly Germany, adversely impacted growth in the quarter.
ACTICOAT() antimicrobial dressings again made substantial progress with sales growing by 40%, and ALLEVYN() dressings and DERMAGRAFT() dermal replacement also saw good sales growth of 10% and 19% respectively.
https://www.primezone.com/newsroom/news_releases.mhtml?d=66958